Holen Sie sich die Stockscreener-App
11.78
1.34%
-0.16
Handel nachbörslich:
11.20
-0.58
-4.92%
Schlusskurs vom Vortag:
$11.94
Offen:
$11.93
24-Stunden-Volumen:
3.11M
Relative Volume:
1.20
Marktkapitalisierung:
$2.05B
Einnahmen:
$61.10M
Nettoeinkommen (Verlust:
$-138.36M
KGV:
-8.7259
EPS:
-1.35
Netto-Cashflow:
$-90.59M
1W Leistung:
+3.24%
1M Leistung:
-9.73%
6M Leistung:
+83.92%
1J Leistung:
+27.77%
1-Tages-Spanne:
$11.34
$12.02
1-Wochen-Bereich:
$10.85
$12.54
52-Wochen-Spanne:
$5.80
$13.85
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Firmenname
Ocular Therapeutix Inc
Sektor
Branche
Telefon
781-357-4000
Adresse
15 CROSBY DRIVE, BEDFORD, MA
Vergleichen Sie OCUL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
11.78 | 2.53B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-15 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-04-08 | Eingeleitet | William Blair | Outperform |
| 2025-03-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-03-11 | Eingeleitet | Needham | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-20 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-05-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-02-09 | Eingeleitet | BofA Securities | Buy |
| 2023-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-08-10 | Fortgesetzt | Berenberg | Buy |
| 2021-08-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-11-13 | Bestätigt | Raymond James | Strong Buy |
| 2020-08-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-03 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | Herabstufung | Cowen | Outperform → Market Perform |
| 2019-05-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-21 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-11-15 | Eingeleitet | Raymond James | Strong Buy |
| 2018-09-07 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-10-24 | Eingeleitet | Guggenheim | Buy |
| 2017-07-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-07-12 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-06-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-08-11 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Ocular Therapeutix Inc Aktie (OCUL) Neueste Nachrichten
Todd Anderman Sells 11,132 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock - MarketBeat
FY2025 EPS Estimate for Ocular Therapeutix Raised by Analyst - MarketBeat
How to track smart money flows in Ocular Therapeutix Inc.July 2025 Fed Impact & AI Driven Price Forecasts - newser.com
Using AI based signals to follow Ocular Therapeutix Inc.Earnings Recap Summary & Safe Investment Capital Preservation Plans - newser.com
Can Ocular Therapeutix Inc. stock maintain growth trajectoryTrade Volume Report & Low Risk Profit Maximizing Plans - newser.com
Ocular Therapeutix (NASDAQ:OCUL) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
What machine learning models say about Ocular Therapeutix Inc.IPO Watch & Trade Opportunity Analysis - newser.com
Published on: 2025-10-10 03:24:04 - newser.com
Using R and stats models for Ocular Therapeutix Inc. forecastingMarket Risk Analysis & Smart Allocation Stock Reports - newser.com
Is Ocular Therapeutix Inc. (0OT) stock considered safe haven2025 Market Outlook & Reliable Breakout Forecasts - newser.com
Price action breakdown for Ocular Therapeutix Inc.2025 Retail Activity & Weekly Stock Breakout Alerts - newser.com
WilmerHale Advised Ocular Therapeutix™ in $475 Million Underwritten Offering - WilmerHale
HC Wainwright & Co. Maintains Ocular Therapeutix (OCUL) Buy Recommendation - Nasdaq
Ocular Therapeutix (OCUL): HC Wainwright & Co. Raises Price Targ - GuruFocus
Piper Sandler Lifts PT on Ocular Therapeutix (OCUL) to $31 From $21 - Yahoo Finance
Ocular Therapeutix, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Ocular Therapeutix (OCUL) Falls Hard on $475-Million Share Sale - MSN
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences - GlobeNewswire
Ocular Therapeutix (NASDAQ:OCUL) Insider Sells $106,472.59 in Stock - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Insider Jeffrey Heier Sells 10,502 Shares - MarketBeat
What analysts say about Ocular Therapeutix Inc stockGap Up/Gap Down Analysis & Free Rapid Wealth Building - earlytimes.in
Why Ocular Therapeutix Inc. (0OT) stock is trending on social mediaLong Setup & Technical Pattern Alert System - newser.com
Ocular Therapeutix (OCUL) Is Down 8.9% After $475M Equity Raise to Fund Axpaxli Trials — Has the Bull Case Changed? - Sahm
Exit strategy if you’re trapped in Ocular Therapeutix Inc.July 2025 Summary & Long-Term Growth Portfolio Plans - newser.com
Will Ocular Therapeutix Inc. stock deliver long term returns2025 Momentum Check & Technical Pattern Recognition Alerts - newser.com
Published on: 2025-10-05 03:10:01 - newser.com
Looking at the Changing Narrative for Ocular Therapeutix After Recent Analyst Updates - Yahoo Finance
Ocular Therapeutix (NASDAQ:OCUL) Stock Rating Upgraded by Zacks Research - MarketBeat
Ocular Therapeutix (OCUL): Exploring Valuation as Investor Interest Grows in Biotech Prospects - Sahm
Ocular Therapeutix (OCUL) Analyst Rating Update: Piper Sandler Raises Price Target | OCUL Stock News - GuruFocus
Ocular Therapeutix (OCUL) Receives Upgraded Price Target from Ba - GuruFocus
Baird Maintains Ocular Therapeutix (OCUL) Outperform Recommendation - Nasdaq
How risky is Ocular Therapeutix Inc. (0OT) stock compared to peersQuarterly Profit Report & Technical Entry and Exit Tips - newser.com
Published on: 2025-10-02 20:18:07 - newser.com
Chardan Capital Maintains Ocular Therapeutix (OCUL) Buy Recommendation - Nasdaq
Ocular Therapeutix (OCUL) Analyst Rating Update: Chardan Capital Maintains Buy | OCUL Stock News - GuruFocus
Ocular Therapeutix's (OCUL) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat
RBC Capital Sticks to Its Buy Rating for Ocular Therapeutix (OCUL) - The Globe and Mail
Needham Maintains Ocular Therapeutix (OCUL) Buy Recommendation - Nasdaq
Ocular Therapeutix (NASDAQ:OCUL) Stock Price Down 5.2%Here's Why - MarketBeat
Needham Raises Price Target for OCUL, Maintains Buy Rating | OCU - GuruFocus
Needham & Company LLC Raises Ocular Therapeutix (NASDAQ:OCUL) Price Target to $20.00 - MarketBeat
JMP Securities Maintains Ocular Therapeutix (OCUL) Market Outperform Recommendation - Nasdaq
Ocular Therapeutix's Axpaxli Drug Trials for Wet AMD Poised for Success, RBC Capital Says - MarketScreener
Is Ocular Therapeutix Inc. forming a reversal patternWeekly Trade Analysis & Fast Moving Stock Trade Plans - newser.com
How Ocular Therapeutix Inc. (0OT) stock responds to job market shiftsWeekly Profit Analysis & Fast Entry Momentum Alerts - newser.com
Ocular Therapeutix, Inc. $OCUL Shares Acquired by Deltec Asset Management LLC - MarketBeat
Ocular Therapeutix prices $475M stock offering - MSN
Ocular Therapeutix reports progress in eye disease treatment trials By Investing.com - Investing.com Nigeria
Ocular Therapeutix Announces Pricing of Underwritten Common Stock Offering - VisionMonday.com
Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock - GlobeNewswire
Finanzdaten der Ocular Therapeutix Inc-Aktie (OCUL)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):